SCHEMBL19627403

SCHEMBL19627403

CC(C)C(=O)NS(=O)(=O)N1CCC(C)(C)CC1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 1/20 0.36
CYP2C19 P33261 1/20 0.36
PIK3C3 Q8NEB9 1/20 0.33
ALDH1A1 P00352 2/20 0.33
MAPT P10636 1/20 0.31
POLB P06746 1/20 0.31
MAPK1 P28482 1/20 0.31
CASP1 P29466 1/20 0.31
CASP7 P55210 1/20 0.31
HSD17B10 Q99714 1/20 0.31
SCN9A Q15858 1/20 0.31
EPHX2 P34913 1/20 0.31
NR1H4 Q96RI1 1/20 0.31
DDIT3 P35638 1/20 0.30
NPSR1 Q6W5P4 1/20 0.30
LMNA P02545 1/20 0.30
HTT P42858 1/20 0.30
GAA P10253 1/20 0.30
CTSS P25774 1/20 0.30
CTSK P43235 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19627404 0.82 MAPT (0.43) ALDH1A1MAPTNPSR1LMNAHTT
SCHEMBL27021617 0.82 MAPT (0.40) ALDH1A1MAPTPOLBMAPK1CASP1
SCHEMBL19631000 0.80 PIK3C3 (0.40) CYP2D6CYP2C19PIK3C3POLBSCN9A
SCHEMBL19627415 0.80 MAPT (0.46) ALDH1A1MAPTPOLBNPSR1LMNA
SCHEMBL19627409 0.80 MAPT (0.46) ALDH1A1MAPTPOLBNPSR1LMNA
SCHEMBL19627365 0.80 CYP2C19 (0.43) CYP2D6CYP2C19MAPTNR1H4GAA
SCHEMBL13712256 0.79 CYP1A2 (0.38) ALDH1A1MAPTPOLBMAPK1CASP1
SCHEMBL27021615 0.77 MEN1 (0.45) POLB
SCHEMBL19631025 0.77 GAA (0.36) CYP2D6CYP2C19PIK3C3SCN9AEPHX2
SCHEMBL19631030 0.76 GAA (0.35) PIK3C3SCN9AEPHX2DDIT3GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170333399-A1 Isoxazole Derivatives as FXR Agonists and Methods of Use Thereof ENANTA PHARMACEUTICALS, INC. 2017-11-23 US disclosed
US-20170333399-A1 Isoxazole Derivatives as FXR Agonists and Methods of Use Thereof ENANTA PHARMACEUTICALS, INC. 2017-11-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170333399-A1 Isoxazole Derivatives as FXR Agonists and Methods of Use Thereof SLC10A1, FXR1, SLC10A2 CYP2D6 402/4885CYP2C19 149/4885PIK3C3 3585/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.